BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wani ZA, Mohapatra S, Khan AA, Mohapatra A, Yatoo GN. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol 2017; 9(5): 270-277 [PMID: 28261384 DOI: 10.4254/wjh.v9.i5.270]
URL: https://www.wjgnet.com/1948-5182/full/v9/i5/270.htm
Number Citing Articles
Lauren R. Shaffer, Nadim Mahmud. Statins in Cirrhosis: Hope or Hype?Journal of Clinical and Experimental Hepatology 2023; 13(6): 1032 doi: 10.1016/j.jceh.2023.05.002
Yue Gu, Xueqin Yang, Hang Liang, Deli Li. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysisBMC Gastroenterology 2019; 19(1) doi: 10.1186/s12876-019-1147-1
Alberto E Muñoz, Florencia D Pollarsky, Mónica Marino, Mariano Cartier, Horacio Vázquez, Pablo Salgado, Gustavo Romero. Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacyWorld Journal of Gastroenterology 2021; 27(28): 4639-4652 doi: 10.3748/wjg.v27.i28.4639
Jordi Gratacós-Ginès, Elisa Pose. Review of the role of statins in cirrhosis and portal hypertensionClinical Liver Disease 2023; 22(2): 50 doi: 10.1097/CLD.0000000000000015
Sasan Sakiani, Theo Heller, Christopher Koh. Current and investigational drugs in early clinical development for portal hypertensionFrontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.974182
Carlos Moctezuma-Velazquez, Juan Gonzalez Abraldes. The Role of Statins in CirrhosisCurrent Treatment Options in Gastroenterology 2022; 20(3): 316 doi: 10.1007/s11938-022-00394-x
Haifu Zhang, Qinxia Zhang, Shuojun Li, Biyun Xie. Simvastatin is Efficacious in Treating CirrhosisJournal of Clinical Gastroenterology 2022; 56(8): e303 doi: 10.1097/MCG.0000000000001732
Damien Leith, Rajeshwar P. Mookerjee. Evidence‐based Gastroenterology and Hepatology 4e2019; : 619 doi: 10.1002/9781119211419.ch41
Robert Schierwagen, Sabine Klein, Frank Uschner, Jonel Trebicka. Novel Targets and Drug Development in Portal HypertensionCurrent Hepatology Reports 2019; 18(2): 187 doi: 10.1007/s11901-019-00462-4
Mohamad Kareem Marrache, Don C. Rockey. Statins for treatment of chronic liver diseaseCurrent Opinion in Gastroenterology 2021; 37(3): 200 doi: 10.1097/MOG.0000000000000716
Shuen Sung, Mustafa Al-Karaghouli, Sylvia Kalainy, Lourdes Cabrera Garcia, Juan G. Abraldes. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosisBMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01704-w
Alberto E. Muñoz, Mariano Cartier, Ayelén B. Kisch. Pharmacotherapy for Liver Cirrhosis and Its Complications2022; : 179 doi: 10.1007/978-981-19-2615-0_12
Carlos Moctezuma-Velázquez, Juan G. Abraldes, Aldo J. Montano-Loza. The Use of Statins in Patients With Chronic Liver Disease and CirrhosisCurrent Treatment Options in Gastroenterology 2018; 16(2): 226 doi: 10.1007/s11938-018-0180-4
Sonia Selicean, Cong Wang, Sergi Guixé-Muntet, Horia Stefanescu, Norifumi Kawada, Jordi Gracia-Sancho. Regression of portal hypertension: underlying mechanisms and therapeutic strategiesHepatology International 2021; 15(1): 36 doi: 10.1007/s12072-021-10135-4
Eric Felli, Yelidousi Nulan, Sonia Selicean, Cong Wang, Jordi Gracia-Sancho, Jaume Bosch. Emerging Therapeutic Targets for Portal HypertensionCurrent Hepatology Reports 2023; 22(1): 51 doi: 10.1007/s11901-023-00598-4